Novo Nordisk (NVO) Stock Tumbles 9% as ZEUS Trial Falls Short of Cardiovascular Goals
Key Highlights Novo Nordisk shares declined more than 9% following disappointing ZEUS cardiovascular trial outcomes. The study demonstrated reduced inflammation markers but failed to decrease







